TSHA is a gene technology medical company which reported on its clinical trials for Rett
Syndrome which is a neurobehavioral disorder separate from others like autism or
schizophrenia. This could be a breakthrough medication for those who suffer from Rett.
TSHA102 could be heralded as a miracle treatment ( not a cure). Price had trended up
in February and...
NASDAQ:MGX
here's an analysis of Metagenomi, Inc.: Chart Data is limited..
Financial Performance:
Market Cap: $456.337 million
Previous Close: $12.25
52 Week Range: $9.74 - $12.74
Volume: 392,654
Avg. Volume: 1,187,350
Recent News:
Introduction:
In the dynamic realm of genetic medicine, where breakthroughs hold the promise of revolutionizing healthcare, one...
KRRO is in the biotechnology space in the gene-editing realm. It is in portfolios of C. Woods .
A recent analyst gave it an upside to 100 which is very favorable given its product line and track
record with an all-time high of about $250 ( which is about 450% over current valuation)
On the one-hour time frame, it has had a great week and is breaking out over...
TNYA has been in consolidation the past two days being in the flag of
a bull flag pattern on the 1H chart. Earnings about six weeks ago were
solid especially for a biotechnology stock which are generally priced
based on future potential and not current performance.
( Fundamentally TNYA is in the gene splicing /slicing place which is
perhaps the most...
BNTC Benitec Biopharma Inc is a development-stage biotechnology company which focuses on the development of novel genetic medicines.
The company develops DNA-directed RNA interference based therapeutics.
BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc. and Morgan Stanley have stakes in it.
On 2/17/2022 P. Trucchio from HC Wainwright brokerage...
AVROBIO is a clinical-stage gene therapy company to treat rare diseases following a single dose worldwide.
AVRO just released positive data on their Phase 1/2 trial testing the safety and efficacy of AVR-RD-04.
73.42% of the shares are controlled by institutional investors, which gives me a lot of trust in the company.
JPMorgan Chase and BlackRock Inc. have...
Hello and welcome to another breakdown of a hot stockpick i've come across with the ticker symbol $QURE. Enjoy and please remember to share!
*this is not investment advice, invest at your own risk*
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy...
Following on strong momentum after Novartis deal, Sangamo Therapeutics with strong open that looks set to breakout the stock from a long sustained downtrend
Look for sustained rally upwards from 50 day average, powerfull buy signal could be triggered and could move the stock closer to its consensus price target of $13.50
www.smarteranalyst.com
NASDAQ:SGMO
investor.sangamo.com
investor.sangamo.com
BLCM has been in continuous long-term downtrend since IPO. Stock price has been showing signs of a bo...
Click here to read the rest of my analysis on BLCM.
Disclosure: I am long BLCM. This is not a recommendation to buy/sell as I am NOT a financial advisor. Please do your homework before investing.
RGNX sold off 12% today on news of a partial clinical hold on an NVS gene therapy trial using its vector.
After reading the press release I think this was an overreaction and the stock price will bounce back swiftly into RGNX earnings catalyst on 11/08/2019. It is sold off right to the bottom of its channel making for a beautiful setup!
Friday, October 11, 2019
ADVM is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,
ADVM is set to present additional clinical data for the first cohort of patients (n=6) in the OPTIC phase 1 clinical trial of ADVM-022, intra-vitreal injection gene therapy in wet age-related macular degeneration (wet AMD) at the...
Recent data release may have changed SGMO's future outlook. Sangamo's long-term chart suggests a potential pullback to $4 is a possibility, but that was before a recent data release by the company for updated Phase 1/2 Results for SB-525 . This is an investigational Hemophilia-A gene therapy that showed sustained increased Factor VIII Levels with no reported...
I have know about this stock for over a year now, but I have never put the time into charting it. The time is near to buy in, and the patient investor will wait for the MACD to bottom out then buy.
